How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?
Elad Ben Meir, Hartmut Grasemann
openalex +1 more source
Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide. [PDF]
Caussy C +9 more
europepmc +1 more source
BIGH3 as a potential biomarker for fibrosis in metabolic dysfunction-associated steatotic liver disease: insights from mouse and human studies. [PDF]
Zhuang Z +10 more
europepmc +1 more source
Liver Fibrosis and Risk of Incident Dementia in the General Population: Systematic Review With Meta-Analysis. [PDF]
Jamalinia M, Zare F, Lonardo A.
europepmc +1 more source
VSIG4 as a novel immune-related diagnostic biomarker and therapeutic target in renal fibrosis. [PDF]
Gao C, Peng F, Xie X, Peng L.
europepmc +1 more source
PROM2 exacerbates CCl4-Induced liver fibrosis via NLRP3 inflammasome activation and hepatocyte pyroptosis. [PDF]
Guo J +10 more
europepmc +1 more source
LGALS3 promotes liver fibrosis by enhancing the expression and phosphorylation of ERK1/2. [PDF]
Zheng X, Yang L, Wang W, Sun J, Li Y.
europepmc +1 more source
Fibrosis in Patients With Choroidal Neovascularization Based on Spectral-Domain Optical Coherence Tomography: Findings From the HARBOR Trial. [PDF]
Adrean SD, Hill L, Amador-Patarroyo J.
europepmc +1 more source

